76
|
Vibert J, Watson S, Benoist C, Waterfall J, Pierron G, Delattre O. Abstract PR16: Comprehensive transcriptomic characterization of 1,400 sarcomas for diagnosis and immune contexture. Cancer Res 2020. [DOI: 10.1158/1538-7445.pedca19-pr16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Sarcomas represent about 15 % of all childhood cancers and are still lethal in a large proportion of cases. They comprise a heterogeneous group of bone and soft tissue tumors with more than 100 distinct histologic entities, often presenting a diagnostic challenge to pathologists.
Methods: To address this pathological complexity and better characterize the molecular biology of sarcomas, we performed whole-transcriptome RNA-seq on frozen tumor tissues as part of the diagnostic workflow for more than 1,400 patients, mainly children and young adults, addressed for sarcoma molecular diagnosis throughout France.
Results: From a clinical perspective, RNA-seq proves to be a powerful complementary test to pathology for diagnosis of sarcomas: it allows agnostic detection of subtype-specific fusion transcripts, as well as diagnostic indication by gene-expression profile clustering. In addition to its diagnostic utility, RNA-seq provides a rich source of information for studying the molecular biology of sarcomas. Indeed, as shown recently in our group, it allows detection of previously uncharacterized sarcoma entities associated with novel fusion genes. Using dimensionality reduction techniques, either linear such as PCA, or nonlinear such as t-SNE or UMAP, we perform unsupervised clustering of our cohort, revealing insights into the global structure of the transcriptomic landscape of sarcomas. We show that many histologic entities have a distinct gene-expression profile, emphasizing the utility of RNA-seq for diagnosis. To explore the immune microenvironment of sarcomas and potential correlates of response to immunotherapy, we deconvolute bulk RNA-seq data to estimate the presence of immune and stromal cell types, allowing a comprehensive characterization of the immune landscape of sarcomas. Finally, we apply state-of-the-art deep learning tools to perform unsupervised clustering and nonlinear dimensional reduction of our RNA-seq samples, allowing a finer and more insightful representation of the structure of the sarcoma transcriptomic landscape.
Conclusion: Besides improving the diagnostic workflow for patients, our comprehensive analysis of sarcoma RNA-seq allows characterization of distinct molecular subtypes and of the immune landscape, opening up perspectives for better diagnosis, classification, and biologic discoveries in sarcoma.
This abstract is also being presented as Poster B75.
Citation Format: Julien Vibert, Sarah Watson, Camille Benoist, Joshua Waterfall, Gaëlle Pierron, Olivier Delattre. Comprehensive transcriptomic characterization of 1,400 sarcomas for diagnosis and immune contexture [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr PR16.
Collapse
|
77
|
Di Gaetano E, Watson S, McBrearty E, Sorel M, Paul DJ. Sub-megahertz linewidth 780.24 nm distributed feedback laser for 87Rb applications. OPTICS LETTERS 2020; 45:3529-3532. [PMID: 32630890 DOI: 10.1364/ol.394185] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 05/25/2020] [Indexed: 06/11/2023]
Abstract
A distributed feedback GaAs-based semiconductor laser with a laterally coupled grating is demonstrated at a wavelength of 780.24 nm with up to 60 mW power. A mode expander and aluminum-free active layers have been used to reduce the linewidth to 612 kHz while maintaining high output power. The laser demonstrates over 40 dB side-mode suppression ratio with >0.3nm of tuning suitable for atom cooling experiments with the D2 87Rb atomic transition. This laser has substantial potential to be integrated into miniaturized cold atom systems.
Collapse
|
78
|
Mir O, Watson S, Blay JY. Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. Neurosurgery 2020; 86:E480-E482. [DOI: 10.1093/neuros/nyaa007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
79
|
Gilford D, Moser S, DePodwin B, Moulton R, Watson S. The Emotional Toll of Climate Change on Science Professionals. ACTA ACUST UNITED AC 2019. [DOI: 10.1029/2019eo137460] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Earth scientists and communicators dealing with or studying climate change face many potential stressors. They need support and resources to maintain and improve their emotional well-being.
Collapse
|
80
|
Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine 2019; 17:100188. [PMID: 31891132 PMCID: PMC6933269 DOI: 10.1016/j.eclinm.2019.10.001] [Citation(s) in RCA: 102] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 09/24/2019] [Accepted: 10/03/2019] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Adverse drug reactions (ADRs) are an important cause of morbidity and mortality. Reports on differences in reporting patterns between women and men exist nationally. The goal of the present study was to assess the global evidence on spontaneous post-marketing ADR reporting differences between reports for women and men. METHODS We analysed data collected within VigiBase, the WHO global database of individual case safety reports, between 1967-2 January 2018. VigiBase contains more than 18 million reports from the 131 member countries of the WHO Programme for International Drug Monitoring. FINDINGS Of the reports with information on sex, 9,056,566 (60.1%) concerned female and 6,012,804 (39.9%) male children and adults. More female ADR reports were submitted in all regions of the world and by all types of reporters. A higher proportion of female reports was seen in all age groups from the age group 12-17 years and older. The largest difference was observed in the age group of 18-44 years and could not be explained by hormonal contraceptive use. The proportion of serious and fatal reports was higher for male reports. INTERPRETATION Global post marketing surveillance data on spontaneous reports indicate that women, from puberty and onwards and especially in their reproductive years, report more ADRs than men. However, there is a higher proportion of serious and fatal ADRs among male reports. Our results suggest important underlying sex-related differences in ADRs. These findings highlight the importance of considering sex throughout the entire life-cycle of drug development and surveillance and understanding the underlying reasons for reporting ADRs.
Collapse
|
81
|
Watson S, Ostiguy N, Cutter CN, Campbel JA. Fate of Salmonella ssp., Listeria monocytogenes, and Campylobacter ssp., During Fermentation and Drying of Duck Salami. MEAT AND MUSCLE BIOLOGY 2019. [DOI: 10.22175/mmb.10821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
ObjectivesCreating artisanal, dry salami products is an increasing trend for charcuterie companies in the United States. These raw, ready-to-eat products are required by USDA-FSIS to have a scientifically valid HACCP system addressing relevant biological hazards. To our knowledge, no literature exists for the validation (at least a 5 Log10 reduction of pathogens per FSIS) of salami products containing duck. Therefore, an experiment was designed to validate the safety of duck salami. The objectives of this study were to validate the safety of fermented and dried duck salami and to investigate if a duck salami manufacturing processes could achieve a 5 LOG10 (CFU/g) reduction of Salmonella ssp., Listeria monocytogenes, and Campylobacter ssp.Materials and MethodsDuck trim and pork belly (70% duck trim, 30% pork belly) were placed in a mixed culture bath approximating three liters. The culture bath was made by growing individually and then combining three strains each of Salmonella spp. and Listeria monocytogenes, two strains of Campylobacter jejuni, and one strain of Campylobacter coli. After inoculation, meat was air dried (30 min @ 23°C), tumbled with one liter of 2.5% BeefxideÒantimicrobial treatment (lactic and citric acid and hydrogen peroxide), and placed in a walk-in cooler (2–4°C) overnight. After inoculation and antimicrobial treatment (∼24 h), the meat was ground (6mm grinding plate) and seasoned with salt (2.5%), cure (NaNO3 & NaNO2), spices, and starter culture. The ground duck-pork mixture was stuffed into 55mm collagen casings, fermented for 48 h (23°C, 95% rH), and dried (12°C, 75% rH) to ∼45% weight loss (approx. 5 wk). Salamis were then vacuum packaged and stored at 23°C (approx. 4 wk). Three independent replications were conducted, and pathogen concentrations, pH, and water activity (aw) were analyzed at Days 0, 1, 2, 3, 5, 10, and weekly until Day 66 during each replication. Critical parameters for production included a final pH less than 5.3 and final aw less than 0.90.ResultsA 5 LOG10(CFU/g) reduction was achieved for all three pathogens. Salmonella achieved a 5.47 LOG10(CFU/g) (p < 0.0001) reduction by Day 38, Listeria monocytogenes achieved a 5.20 LOG10(CFU/g) (p < 0.0001) reduction by Day 59, and Campylobacter achieved a 6.85 LOG10(CFU/g) (p < 0.0001) reduction by Day 45. Final reductions of 7.03 (p < 0.0001), 5.90 (p < 0.0001), and 7.19 (p < 0.0001) LOG10(CFU/g) were achieved for Salmonella spp., Listeria monocytogenes, and Campylobacter spp., respectively. During the entire fermentation and drying process, populations of each species never increased by more than 1 LOG10 (CFU/cm2). A final pH of 5.11 and a final aw of 0.81 were also achieved.ConclusionThe results of this study indicate that the parameters used to ferment and dry this product are able to achieve a 5 LOG10 (CFU/g) reduction of each pathogen to validate the safe production of duck salami.
Collapse
|
82
|
Johal A, Loftus I, Boyle J, Naylor R, Watson S, Heikkila K. Changing Patterns of Carotid Endarterectomy Between 2011 and 2017 in England: A Population-Based Cohort Study. J Vasc Surg 2019. [DOI: 10.1016/j.jvs.2019.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
83
|
Myers K, Watson S, Weeks B, Weis L, Beck B. Are musculoskeletal benefits of 8 months high-intensity exercise maintained in postmenopausal women with low bone mass? LIFTMOR trial follow-up. J Sci Med Sport 2019. [DOI: 10.1016/j.jsams.2019.08.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
84
|
Baggus EMR, Hadjivassiliou M, Cross S, Penny H, Urwin H, Watson S, Woodward JM, Sanders DS. How to manage adult coeliac disease: perspective from the NHS England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease. Frontline Gastroenterol 2019; 11:235-242. [PMID: 32419915 PMCID: PMC7223293 DOI: 10.1136/flgastro-2019-101191] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 07/03/2019] [Accepted: 07/21/2019] [Indexed: 02/06/2023] Open
Abstract
Adult coeliac disease (CD) affects approximately 1% of the population. Most patients diagnosed will respond to a gluten-free diet; however, up to 30% may have persisting symptoms. Such patients may have ongoing issues associated with adherence, non-responsive CD or refractory CD. This article provides a clinical overview of how to manage this group of patients with persisting symptoms, including an investigational algorithm and details of how to contact the National Health Service England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease. We hope this will be a valuable source of contemporary information for all UK gastroenterologists and internationally.
Collapse
|
85
|
Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C. Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52]. Eur J Cancer 2019; 118:190. [PMID: 31331779 DOI: 10.1016/j.ejca.2019.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
86
|
Kendall GC, Watson S, Xu L, LaVigne C, Murchison W, Rakheja D, Tirode F, Delattre O, Amatruda J. Abstract 872: Genetic models reveal that the novel VGLL2-NCOA2 fusion oncogene leverages embryonic programs for sarcomagenesis. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer characterized by a misregulation of skeletal muscle developmental pathways. To date, identified oncogenic drivers predominantly include RAS mutations or chromosomal translocations and gene fusions between PAX3 or PAX7 and FOXO1. RNAseq analysis of sarcomas with non-canonical gene fusions has identified new potential genetic drivers of tumorigenesis that have not been rigorously functionally validated for their transformation capacity and biological activity. One new fusion is a chromosomal translocation and inversion between chromosomes 6 and 8, which acts to juxtapose two transcriptional co-activators, VGLL2 and NCOA2. This VGLL2-NCOA2 fusion was identified in congenital rhabdomyosarcoma clinical cohorts by us and others, and characterizes aggressive RMS that express MYOD and MYOG histological markers. However, evidence of VGLL2-NCOA2 transformation capacity has not been verified, hindering insights into its functional contributions to tumorigenesis. Here, we interrogate the function ofVGLL2-NCOA2 using complementary genomic patient data and zebrafish model systems. We utilized the Tol2 transposon system to express mosaic human VGLL2-NCOA2 during early development, and found that VGLL2-NCOA2 is sufficient for tumorigenesis, and results in aggressive tumors with high penetrance by 75 days of age in zebrafish. Further, the histology of zebrafish tumors resembles the human disease, and tumors express markers indicative of RMS such as myog and desma. A cross-species RNAseq of patient and zebrafish VGLL2-NCOA2 RMS tumors highlights a significant enrichment and overlap between gene expression signatures. Finally, mapping the gene expression signatures of VGLL2-NCOA2 zebrafish RMS tumors along the spectrum of zebrafish embryogenesis indicates a clustering with developmental stages corresponding to early somitogenesis, highlighting their arrested developmental nature. Hence, we have generated the first animal model of human VGLL2-NCOA2 tumorigenesis, and have applied this model to understand the biology and identify potential therapeutic targets for this newly identified disease.
Citation Format: Genevieve C. Kendall, Sarah Watson, Lin Xu, Collette LaVigne, Whitney Murchison, Dinesh Rakheja, Franck Tirode, Olivier Delattre, James Amatruda. Genetic models reveal that the novel VGLL2-NCOA2 fusion oncogene leverages embryonic programs for sarcomagenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 872.
Collapse
|
87
|
Telford R, Nichols M, Watson S. C7 Improving Pain Management through the Creation and Commitment of a Pain Resource Nurse Program. Pain Manag Nurs 2019. [DOI: 10.1016/j.pmn.2018.11.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
88
|
Watson S, Ostiguy N, Cutter CN, Campbel JA. Fate of Salmonella ssp., Listeria monocytogenes, and Campylobacter ssp., During Fermentation and Drying of Duck Salami. MEAT AND MUSCLE BIOLOGY 2019. [DOI: 10.22175/mmb2019.0134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
89
|
Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C. Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). Eur J Cancer 2018; 107:46-52. [PMID: 30529902 DOI: 10.1016/j.ejca.2018.11.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 10/23/2018] [Accepted: 11/01/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND 5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA). Nanoparticle albumin-bound (Nab-) paclitaxel is active in advanced disease but has never been evaluated in the perioperative setting. The objective was to evaluate the efficacy of Nab-paclitaxel in combination with FOLFOX for RGA patients. METHODS We performed a non-randomised, open-label, phase II study. RGA patients were assigned to receive neoadjuvant Nab-paclitaxel (150 mg/m2) and FOLFOX q2w for six cycles. Six additional post-operative cycles were kept at the investigator's discretion. The primary end-point was complete pathological response (tumour regression grade [TRG1]) rate. According to Fleming design, 49 patients were required to test H0 (10% TRG1) and H1 (25% TRG1). To reject H0, TRG1 had to be achieved in 8 patients. RESULTS Forty-nine patients were included. Median number of neoadjuvant chemotherapy cycles was 6 (range, 3-6). Median dose intensity for Nab-paclitaxel, oxaliplatin and 5-FU was 96% (38-103%), 97% (47-103%) and 99% (50-112%), respectively. Surgery could not be performed in 5 (10.2%) patients. Tumour resection was R0 for 42 of 44 (95.5%) patients. Pathological review classified tumours as TRG1 to TRG5 for 8 (16.3%), 11 (22.5%), 4 (8.2%), 18 (36.7%) and 3 (6.1%) patients, respectively. Grade 3 or worse toxicities during neoadjuvant chemotherapy were non-febrile neutropenia (20.4%), nausea (8.2%), diarrhoea (8.2%) and neuropathy (6.1%). Of 44 patients, 14 (31.8%) experienced surgery-related complications and three (6.8%) died of surgical complications. CONCLUSION This regimen shows promising activity. Toxicity is manageable but a meaningful rate of surgical complications was observed. This strategy deserves investigation in phase III studies.
Collapse
|
90
|
Chauhan A, Lalor T, Watson S, Adams D, Farrah TE, Anand A, Kimmitt R, Mills NL, Webb DJ, Dhaun N, Kalla R, Adams A, Vatn S, Bonfliglio F, Nimmo E, Kennedy N, Ventham N, Vatn M, Ricanek P, Halfvarson J, Soderhollm J, Pierik M, Torkvist L, Gomollon F, Gut I, Jahnsen J, Satsangi J, Body R, Almashali M, McDowell G, Taylor P, Lacey A, Rees A, Dayan C, Lazarus J, Nelson S, Okosieme O, Corcoran D, Young R, Ciadella P, McCartney P, Bajrangee A, Hennigan B, Collison D, Carrick D, Shaukat A, Good R, Watkins S, McEntegart M, Watt J, Welsh P, Sattar N, McConnachie A, Oldroyd K, Berry C, Parks T, Auckland K, Mentzer AJ, Kado J, Mirabel MM, Kauwe JK, Robson KJ, Mittal B, Steer AC, Hill AVS, Akbar M, Forrester M, Virlan AT, Gilmour A, Wallace C, Paterson C, Reid D, Siebert S, Porter D, Liversidge J, McInnes I, Goodyear C, Athwal V, Pritchett J, Zaitoun A, Irving W, Guha IN, Hanley NA, Hanley KP, Briggs T, Reynolds J, Rice G, Bondet V, Bruce E, Crow Y, Duffy D, Parker B, Bruce I, Martin K, Pritchett J, Aoibheann Mullan M, Llewellyn J, Athwal V, Zeef L, Farrow S, Streuli C, Henderson N, Friedman S, Hanley N, Hanley KP. Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. QJM 2018; 111:920-924. [PMID: 31222346 DOI: 10.1093/qjmed/hcy193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
91
|
Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, Star K, van Hunsel F. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Drug Saf 2018; 41:203-212. [PMID: 28933055 PMCID: PMC5808049 DOI: 10.1007/s40264-017-0594-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Introduction Patient reporting in pharmacovigilance is important and contributes to signal detection. However, descriptions of methodologies for using patient reports in signal detection are scarce, and published experiences of how patient reports are used in pharmacovigilance are limited to a few individual countries. Objective Our objective was to explore the contribution of patient reports to global signal detection in VigiBase. Methods Data were retrieved from VigiBase in September 2016. Drug–event-combination series were restricted to those with >50% patient reports, defined as reporter type “Consumer/non-health professional” per E2B reporting standard. vigiRank was applied to patient reports to prioritize combinations for assessment. Product information for healthcare professionals (HCPs) as well as patient information leaflets (PILs) were used as reference for information on adverse drug reactions (ADRs). Staff from the Uppsala Monitoring Centre and the Netherlands Pharmacovigilance Centre Lareb categorized the combinations. Potential signals proceeded to a more in-depth clinical review to determine whether the safety concern should be communicated as a “signal.” Results Of the 212 combinations assessed, 20 (9%) resulted in eight signals communicated within the World Health Organization (WHO) programme for international drug monitoring. Review of PILs revealed insufficient ADR descriptions for patients and examples of poor consistency with product information for HCPs. Patient narratives provided details regarding the experience and impact of ADRs and evidence that patients make causality and personal risk assessments. Conclusions Safety concerns described in patient reports can be identified in a global database including previously unknown ADRs as well as new aspects of known ADRs. Patient reports provide unique information valuable in signal assessment and should be included in signal detection. Novel approaches to highlighting patient reports in statistical signal detection can further improve the contribution of patient reports to pharmacovigilance.
Collapse
|
92
|
Watson S, Menis J, Baldini C, Martin-Romano P, Michot JM, Hollebecque A, Armand JP, Massard C, Soria JC, Postel-Vinay S, Paoletti X. Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? Br J Cancer 2018; 119:937-939. [PMID: 30327567 PMCID: PMC6203755 DOI: 10.1038/s41416-018-0245-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2018] [Revised: 08/02/2018] [Accepted: 08/03/2018] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Reliable evaluation of treatment benefit in early phase clinical trials is necessary. The time to progression ratio (TTPr), which compares successive TTP in a single patient, is a powerful criteria for determining targeted or immune therapies efficacy. METHODS We evaluated 205 TTPr in a large cohort of 177 advanced cancer patients enrolled in at least two Phase 1/1b trials (out of 2827 phase 1/1b-treated patients) at Gustave Roussy. RESULTS This first wide description of TTPr showed that, under the hypothesis of overall absence of treatment line effect, the median TTPr was 0.7 and that 25% of patients presented a TTPr above the conventional efficacy threshold of 1.3. CONCLUSIONS A higher median TTPr and a larger proportion of patients above the 1.3 threshold should therefore be achieved to conclude to drug efficacy. New guidelines for TTPr interpretation and calibration are proposed, which warrant independent prospective validation.
Collapse
|
93
|
Zamiri M, Watson S. Loricrin palmoplantar keratoderma: full-thickness skin grafting for pseudoainhum. Clin Exp Dermatol 2018; 44:444-446. [PMID: 30264492 DOI: 10.1111/ced.13770] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/28/2018] [Indexed: 11/29/2022]
|
94
|
Thuleau A, Dugay J, Dacremont C, Jemmali Z, Elard J, De Ricke Y, Cassoux N, Watson S, Escande MC, Fromantin I. Volatile Organic Compounds of Malignant Breast Cancer Wounds: Identification and Odors. WOUNDS : A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE 2018; 30:337–344. [PMID: 30380523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
INTRODUCTION During the metabolic processes of malignant wounds, bacteria produce a large amount of volatile organic compounds (VOCs) that are responsible for malodors and may have a major impact on the patient's quality of life with a risk of isolation. OBJECTIVE A translational study was conducted on 32 malignant breast wounds by combining the identification of bacterial strains present on wounds, the identification of VOCs produced by these bacterial strains, and sensory evaluation to assess odor intensity and quality of odorous bacteria. MATERIALS AND METHODS Thirty-two patients with malignant breast cancer wounds > 10 cm2 at various stages of the disease (curative or palliative) were included in the protocol. Volatile organic compounds were collected from primary dressings by headspace solid-phase microextraction and then analyzed by gas chromatography separation coupled with a mass spectrometer detector analysis. Microbiological samplings were taken and analyzed on agar plates. The odors of selected bacteria were assessed by a panel of staff members. RESULTS Proteus mirabilis and Fusobacterium necrophorum seem to produce the strongest and most typical malignant wound odor. The VOCs were analyzed and dimethyl disulfide, dimethyl trisulfide, phenol, indole, and 3-methylbutanal were found to be produced by bacteria generating the most typical wound odor. CONCLUSIONS This study suggests the bacteria present in wounds may be responsible for odors. In addition, these findings could pave the way to engineer new types of dressings and to develop an evaluation method to assess their efficiency both quantitatively and qualitatively as well as improve quality of palliative care and comfort for women with malignant wounds.
Collapse
|
95
|
Hughes M, Moore T, Manning J, Wilkinson J, Watson S, Samraj P, Dinsdale G, Roberts C, Rhodes LE, Herrick AL, Murray A. A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis. J DERMATOL TREAT 2018; 30:251-257. [PMID: 29862855 PMCID: PMC6484448 DOI: 10.1080/09546634.2018.1484875] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. Methods: A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm2 twice weekly for 3 weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented. Patient opinion on time to deliver, feasibility, and pain visual analogue score (VAS; 0–100, 100 most severe) was collected. Patient and clinician DU global assessment VAS were documented. DUs were evaluated by laser Doppler perfusion imaging pre- and post-irradiation. Results: In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT ‘took just the right amount of time’ and was ‘feasible’, with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: –7.1 and –5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. Conclusions: LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy.
Collapse
|
96
|
Kendall GC, Watson S, Xu L, LaVigne CA, Murchison W, Rakheja D, Skapek SX, Tirode F, Delattre O, Amatruda JF. PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. eLife 2018; 7:33800. [PMID: 29869612 PMCID: PMC5988421 DOI: 10.7554/elife.33800] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 03/25/2018] [Indexed: 12/23/2022] Open
Abstract
Alveolar rhabdomyosarcoma is a pediatric soft-tissue sarcoma caused by PAX3/7-FOXO1 fusion oncogenes and is characterized by impaired skeletal muscle development. We developed human PAX3-FOXO1 -driven zebrafish models of tumorigenesis and found that PAX3-FOXO1 exhibits discrete cell lineage susceptibility and transformation. Tumors developed by 1.6–19 months and were primitive neuroectodermal tumors or rhabdomyosarcoma. We applied this PAX3-FOXO1 transgenic zebrafish model to study how PAX3-FOXO1 leverages early developmental pathways for oncogenesis and found that her3 is a unique target. Ectopic expression of the her3 human ortholog, HES3, inhibits myogenesis in zebrafish and mammalian cells, recapitulating the arrested muscle development characteristic of rhabdomyosarcoma. In patients, HES3 is overexpressed in fusion-positive versus fusion-negative tumors. Finally, HES3 overexpression is associated with reduced survival in patients in the context of the fusion. Our novel zebrafish rhabdomyosarcoma model identifies a new PAX3-FOXO1 target, her3/HES3, that contributes to impaired myogenic differentiation and has prognostic significance in human disease. One of the most common cancers in children and adolescents is rhabdomyosarcoma, a cancer of soft tissue such as muscle, tendon or cartilage. The fusion of DNA on two different chromosomes causes the most aggressive form of rhabdomyosarcoma. The fused DNA produces an abnormal protein called PAX3-FOXO1. During normal muscle development, a subset of rapidly growing cells eventually slow down and form mature, working muscle cells. It is still unclear how exactly rhabdomyosarcoma develops, but it is thought that PAX3-FOXO1 stops muscle cells from maturing and the cells that grow out of control result in a tumor. Learning how PAX3-FOXO1 hijacks normal muscle development could lead to new treatments for rhabdomyosarcoma. One treatment approach is to slow the growth of a tumor and force the cells to mature. Then, young patients might avoid chemotherapy or radiation treatments and their side effects. Efforts to improve treatment for this type of cancer face several obstacles. Currently, only one vertebrate animal model of the disease is available to test drugs, and it is still not known how PAX3-FOXO1 causes healthy cells to become cancerous. It is also hard to turn off PAX3-FOXO1 itself, so scientists must find additional proteins that collaborate with it to target with drugs. Now, Kendall et al. show that genetically engineered zebrafish with human PAX3-FOXO1 develop rhabdomyosarcoma-like tumors. Experiments on these zebrafish showed that the protein turns on a gene called her3. Humans have a similar gene called HES3. In zebrafish or mouse cells, human HES3 interferes with muscle-cell maturation and allows cells that acquire PAX3-FOXO1 to persist during development instead of dying. It also increases the cell growth and cancerous behavior in human tumor cells. Kendall et al. further looked at HES3 levels in tumors collected from patients with rhabdomyosarcoma and found that having higher levels of HES3 increased the risk of death from the cancer. Human rhabdomyosarcoma tumors with high HES3 levels were also more likely to have certain cell-growth and cell-differentiation related proteins. Drugs that turn off or modify the activity of these proteins already exist. Testing these drugs that target processes such as cell growth in the zebrafish with rhabdomyosarcoma-like tumors may help scientists determine if they reduce tumor growth. If they do, additional trials could determine if they would help patients with rhabdomyosarcoma.
Collapse
|
97
|
Watson S, Härmark L. Desogestrel and panic attacks - a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports. Br J Clin Pharmacol 2018; 84:1858-1859. [PMID: 29797731 PMCID: PMC6046470 DOI: 10.1111/bcp.13617] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 03/28/2018] [Accepted: 04/12/2018] [Indexed: 11/30/2022] Open
|
98
|
Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, Tirode F. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol 2018; 245:29-40. [PMID: 29431183 DOI: 10.1002/path.5053] [Citation(s) in RCA: 215] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 01/10/2018] [Accepted: 02/02/2018] [Indexed: 01/02/2023]
Abstract
Sarcoma represents a highly heterogeneous group of tumours. We report here the first unbiased and systematic search for gene fusions combined with unsupervised expression analysis of a series of 184 small round cell sarcomas. Fusion genes were detected in 59% of samples, with half of them being observed recurrently. We identified biologically homogeneous groups of tumours such as the CIC-fused (to DUX4, FOXO4 or NUTM1) and BCOR-rearranged (BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR, and BCOR internal duplication) tumour groups. VGLL2-fused tumours represented a more biologically and pathologically heterogeneous group. This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities. We also describe a completely novel group of epithelioid and spindle-cell rhabdomyosarcomas characterized by EWSR1- or FUS-TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
|
99
|
Baillargeon KR, Meserve K, Faulkner S, Watson S, Butts H, Deighan P, Gerdon AE. Precipitation SELEX: identification of DNA aptamers for calcium phosphate materials synthesis. Chem Commun (Camb) 2018; 53:1092-1095. [PMID: 28045140 DOI: 10.1039/c6cc08687j] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
DNA aptamers that enhance calcium phosphate mineral formation were identified using a novel precipitation SELEX method. The evolved DNA library was substantially enriched in G nucleotides and in predicted G-quadruplex structures, suggesting their importance in the mechanism of mineralization. This work could readily be extended to provide additional novel DNA aptamers for materials synthesis.
Collapse
|
100
|
Watson S, Kendall GC, Murchison WA, Delattre O, Tirode F, Amatruda JF. Abstract PR06: Functional genomics of CIC-DUX4 fusions in zebrafish recapitulates the spectrum of human CIC-rearranged cancers. Clin Cancer Res 2018. [DOI: 10.1158/1557-3265.sarcomas17-pr06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CIC-DUX4 sarcomas are aggressive soft-tissue malignancies characterized by frequent metastases and poor survival. Histologically, CIC-DUX4 sarcomas resemble Ewing sarcomas but do not express EWS-FLI1 or other FET-ETS fusion genes typical of Ewing sarcoma. The tumors arise from chromosomal translocations that fuse the transcriptional repressor CIC with the homeodomain-containing protein DUX4, creating an aberrant transcription factor. However, the critical targets of CIC-DUX4 have been only partly described, the cell of origin and mechanism of transformation are unknown, and animal models of the disease are lacking. Owing to this poor biologic understanding, patients with CIC-DUX4 sarcomas are treated with the same regimens used for classical Ewing sarcoma, despite generally poor outcomes.
To comprehensively address these problems, we are taking a cross-species comparative oncology approach via analysis of human CIC-DUX4 sarcomas and genetically engineered in vivo zebrafish models. Human CIC-DUX4 transgenes exerted strong effects on zebrafish embryonic development. Beginning at 5 weeks of age, almost 40% of injected animals developed invasive, rapidly growing tumors. Strikingly, two classes of tumors emerged: small round blue cell sarcomas developed in soft tissues including the trunk musculature and the ventral abdomen, and CNS-PNETs arose in the head. This recapitulates the spectrum of human tumors with CIC gene rearrangements. To further understand the molecular mechanisms of tumorigenesis, we performed RNASeq on zebrafish CIC-DUX4 sarcoma and zebrafish EWS-FLI1 sarcomas alongside human tumors and nonmalignant tissues. This analysis revealed pathways conserved between fish and human, including RAS-MAPK signaling, and highlighted the central importance of ETV4 in this disease. Further studies established ETV4 as a valuable new marker of the human disease. Taken together these findings demonstrate that CIC-DUX4 expression is sufficient to promote the development of tumors, give insight into the cellular origins of CIC-DUX4 tumors, and provide a valuable new animal model for translational research.
Citation Format: Sarah Watson, Genevieve C. Kendall, Whitney A. Murchison, Olivier Delattre, Franck Tirode, James F. Amatruda. Functional genomics of CIC-DUX4 fusions in zebrafish recapitulates the spectrum of human CIC-rearranged cancers [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr PR06.
Collapse
|